Dostarlimab Achieves 100% Clinical Complete Response in Rectal Cancer Trial

A recent study found that all patients with rectal cancer in the trial experienced a clinical complete response after receiving dostarlimab in the neoadjuvant setting. These findings suggest a potential benefit of dostarlimab as a neoadjuvant treatment for this specific patient population. Researchers observed the 100% clinical complete response in patients with rectal cancer following neoadjuvant treatment with dostarlimab. This means that after the treatment, no evidence of the tumor could be detected through physical examination, endoscopy, or imaging scans. The study followed patients who received dostarlimab prior to standard treatment options like chemotherapy or surgery.

Newsflash | Powered by GeneOnline AI
Date: April 28, 2025

Author

Mark Chiang